20161020 – Capital increase EN FINAL
Category: dates
First Patient Randomized in Multiple Dose Cohort of Phase 1/1b Trial with Transgene’s TG1050 in Chronic Hepatitis B Patients
20161017-tg1050-md-us-final
Transgene Announces Collaboration with Merck and Pfizer to Evaluate the Combination of TG4001 with Avelumab in HPV-Positive Head & Neck Cancer in a Phase 1/2 Study
alliance_transgene-collab-press-release_row
Engineering Oncolytic Vaccinia Virus with Improved Cancer Killing Abilities
Johann Foloppe, et al. 10th International Meeting on Replicating Oncolytic Virus Therapeutics, Vancouver, Canada – 1-4 October 2016 Download the poster here Poster Presentation Collaboration between Transgene – HTS facility IGBMC, Illkirch – France IREBS, Illkirch, France – ICube, Strasbourg, France
Transgene presents data on improved cytotoxic activity of oncolytic viruses expressing intrabodies in resistant tumor cell lines
20161005-ov-vancouver-vacv-antibody-poster-final-us
Transgene Provides an Update on its Development Strategy and on its First Half-Year 2016 Financials
20160905 – H1 update – EN – V10
Transgene Announces Participation at Upcoming Investor Events
20160901 – Next investor events – EN
Transgene to Continue Phase 1/1b Study with TG1050 in Chronic Hepatitis B Patients on the Recommendation of the Trial’s Safety Review Committee
20160721 – Safety TG1050 EN Vdef
Oncolytic vaccinia virus TG6002 demonstrates potent efficiency in pancreatic tumor alone and in combination with standard chemotherapies
Johann Foloppe, et al. XXI International Poxvirus, Asfavirus and Iridovirus Conference Le Bischenberg (France) 1-5 July 2016 Download the poster here Poster Presentation
Evaluation of a novel oncolytic Raccoonpox virus expressing the bifunctional FCU1 suicide gene
Marine Ricordel, et al. XXI International Poxvirus, Asfavirus and Iridovirus Conference Le Bischenberg (France) 1-5 July 2016 Download the poster here Poster Presentation